secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2026-08-04T12:46:07+00:00
Accession:  0001570562-26-000083
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus expands Estyme HA gel rights to Canada, Australia, New Zealand; expects 2028 launch
--------------------------------------------------------------------------------

- Upfront payment of €920,000 plus up to €1.38 million upon regulatory approvals.
- Estyme complements Jeuveau/Nuceiva; combined neurotoxin & filler TAM ~$500M annually.
- Commercialization expected in 2028, subject to applicable regulatory approvals.
- Symatese responsible for development, manufacturing, and regulatory; Evolus pays mid-single digit royalty.
- Agreement expected to be accretive to Evolus' international gross margins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056226000083/0001570562-26-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056226000083/eols-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001570562-26-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer